This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sulforaphane Supplementation in Atopic Asthmatics (brasma)

This study has been completed.
Information provided by (Responsible Party):
Michelle Hernandez, MD, University of North Carolina, Chapel Hill Identifier:
First received: April 17, 2013
Last updated: March 7, 2016
Last verified: March 2016
The investigators will perform a pilot study of daily treatment with oral sulforaphane (SFN) for 3 days to determine if Nuclear factor (erythroid-derived 2)-like 2 (NRF2) induction is possible with this supplementation regimen in individuals with allergic asthma.

Condition Intervention Phase
Asthma Dietary Supplement: Alpha Sprout Homogenate Dietary Supplement: Sulforaphane Homogenate Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Sulforaphane Supplementation in Atopic Asthmatics

Further study details as provided by Michelle Hernandez, MD, University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • mRNA levels of NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells [ Time Frame: 2 hours post third ingestion of SFN/placebo ingestion ]

Enrollment: 16
Study Start Date: April 2013
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sulforaphane-rich supplement
Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
Dietary Supplement: Sulforaphane Homogenate
Placebo Comparator: Alfalfa Sprout Homogenate
Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
Dietary Supplement: Alpha Sprout Homogenate
Alpha Sprout Homogenate
Other Name: Placebo

Detailed Description:
This pilot study will examine if oral SFN supplementation can induce NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells of allergic asthmatics. Subjects will receive both a SFN-rich broccosprout homogenate preparation and an alfalfa sprout homogenate (placebo) in a crossover fashion. mRNA levels of NRF2 and NRF2-dependent phase II enzymes will be compared between the active and placebo periods.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-50 of both genders
  2. History of episodic wheezing, chest tightness, or shortness of breath after age of 6 years consistent with asthma, or physician diagnosed asthma after age of 6 years.
  3. AND: Positive methacholine test. A positive test is defined as a provocative concentration of methacholine of 10 mg/ml or less producing a 20% fall in FEV1 (PC20 methacholine). Methacholine challenge in a separate screening protocol (98-0799), or from other venues will be accepted.
  4. OR: Pre and post bronchodilator FEV1 improvement by 12% or more after 4 puffs of albuterol inhaler.
  5. FEV1 of at least 80% of predicted and FEV1/FVC ratio of at least .70 (without use of bronchodilating medications for 12 hours), consistent with lung function of persons with no more than mild episodic or mild persistent asthma (NHANES III predicted set).
  6. Allergic sensitization to at least one of the following allergen preparations: (House Dust Mite f, House dust mite p, Cockroach, Tree mix, Grass Mix, Weed Mix, Mold Mix 1, Mold Mix 2, Rat, Mouse, Guinea Pig, Rabbit, Cat or Dog) confirmed by positive immediate skin test response in a separate screening protocol. Proof of allergy from other venues, including ImmunoCAP testing from a medical workup, provided by the subject, will be accepted.
  7. Oxygen saturation of > 94 % and normal blood pressure (Systolic between 150 - 90, Diastolic between 90-60 mm Hg)
  8. Willing to provide information regarding health history and habits of cigarette smoke exposure;
  9. Willing to avoid antioxidant vitamins and cruciferous vegetables as well as juices/drinks with added vitamin supplements for 2 days prior the baseline screening visit and throughout initial dosing period.
  10. Subjects must be willing to avoid antihistamine use for 4 days prior to each session and NSAIDs for 7 days prior to each session. Nasal steroids must be held for 2 weeks prior to the session.

Exclusion Criteria:

  1. Medical history or underlying health problems that preclude participation in the protocol per the study physician;
  2. Current nutritional disorder such as anorexia, bulimia, irritable bowel syndrome, Crohn's disease etc;
  3. Use of oral corticosteroids within the past 4 weeks;
  4. Presence of upper or lower respiratory tract infection or treatment with antibiotics within the previous 4 weeks;
  5. Pregnancy as determined by menstrual history or urine pregnancy test;
  6. Current smokers will be excluded. Anyone with a smoking history > 0.5 pack year and/or >1 pack per month will also be excluded.
  7. History of bleeding disorder;
  8. Recent nasal surgery (with 6 months). If a subject has had nasal surgery between 6 months and 5 years, a study physician will visualize the area prior to the biopsy to evaluate the suitability of the nose for the procedure.
  9. History of intolerance of or aversion to broccoli
  10. Unable to withhold nasal steroids for 2 weeks before each session. These subjects may be deferred until after their allergy season.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01845493

United States, North Carolina
Environmental Protection Agency at the University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Principal Investigator: Michelle L Hernandez, MD center for environmental medicine asthma and lung biology
  More Information

Responsible Party: Michelle Hernandez, MD, Principle Investigator, University of North Carolina, Chapel Hill Identifier: NCT01845493     History of Changes
Other Study ID Numbers: 13-0056
Study First Received: April 17, 2013
Last Updated: March 7, 2016

Keywords provided by Michelle Hernandez, MD, University of North Carolina, Chapel Hill:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents processed this record on July 21, 2017